TRVI
Trevi Therapeutics, Inc.
NasdaqGMUSDEQUITY
DELAYED
Last price
18.15
▼ 0.10 (0.55%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
18.49
Prev close
18.25
Day high
18.54
Day low
17.84
Volume
1.08M
Market cap
—
P/E (TTM)
—
52W range
6.93 – 20.22
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-2.71%
-1.3%
1M
+4.54%
+0.8%
3M
+26.84%
+23.7%
6M
+68.80%
+57.7%
YTD
+43.45%
+31.2%
1Y
+142.05%
+122.1%
3Y
+661.02%
+586.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $33.48M | $39.38M | $23.68M | $19.83M | -15.0% |
| Selling, general & admin | $15.85M | $12.15M | $10.24M | $10.07M | +30.5% |
| Total operating expense | $49.33M | $51.52M | $33.92M | $29.91M | -4.3% |
| Operating income | -$49.33M | -$51.52M | -$33.92M | -$29.91M | +4.3% |
| Net interest income | $6.54M | $3.60M | $4.36M | $577.00K | +81.7% |
| Pre-tax income | -$42.82M | -$47.94M | -$29.10M | -$29.19M | +10.7% |
| Tax provision | -$64.00K | -$30.00K | -$32.00K | -$36.00K | -113.3% |
| Net income | -$42.76M | -$47.91M | -$29.07M | -$29.15M | +10.8% |
| Net income to common | -$42.76M | -$47.91M | -$29.07M | -$29.15M | +10.8% |
| Basic EPS | -0.32 | -0.47 | -0.29 | -0.45 | +31.9% |
| Diluted EPS | -0.32 | -0.47 | -0.29 | -0.45 | +31.9% |
| EBIT | -$42.82M | -$47.94M | -$28.71M | -$28.02M | +10.7% |
| EBITDA | -$42.68M | -$47.79M | -$28.58M | -$27.98M | +10.7% |
| Basic shares | 134.75M | 101.97M | 99.03M | 64.54M | +32.1% |
| Diluted shares | 134.75M | 101.97M | 99.03M | 64.54M | +32.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.91M | $34.10M | $32.40M | $12.59M | — | -44.5% |
| Cash & short-term investments | $188.26M | $107.62M | $82.97M | $120.51M | — | +74.9% |
| Total current assets | $191.66M | $109.43M | $87.55M | $122.62M | — | +75.1% |
| Property, plant & equipment | $855.00K | $1.23M | $1.56M | $194.00K | — | -30.4% |
| Total assets | $193.44M | $110.90M | $89.40M | $123.02M | — | +74.4% |
| Total current liabilities | $9.75M | $10.51M | $5.82M | $13.40M | — | -7.2% |
| Current debt | — | — | — | $7.00M | $5.83M | — |
| Long-term debt | — | — | — | $2.15M | $8.65M | — |
| Total debt | $753.00K | $1.03M | $1.34M | $9.18M | — | -27.0% |
| Total liabilities | $10.20M | $11.26M | $6.86M | $15.56M | — | -9.4% |
| Retained earnings | -$329.80M | -$287.05M | -$239.13M | -$210.07M | — | -14.9% |
| Shareholder equity | $183.24M | $99.64M | $82.55M | $107.46M | — | +83.9% |
| Working capital | $181.91M | $98.92M | $81.72M | $109.22M | — | +83.9% |
| Net tangible assets | $183.24M | $99.64M | $82.55M | $107.46M | — | +83.9% |
| Shares issued | 128.31M | 93.60M | 68.28M | 59.94M | — | +37.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$42.76M | -$47.91M | -$29.07M | -$29.15M | +10.8% |
| Depreciation & amortisation | $144.00K | $147.00K | $123.00K | $43.00K | -2.0% |
| Stock-based compensation | $5.18M | $3.59M | $2.25M | $2.33M | +44.5% |
| Change in working capital | -$3.49M | $6.83M | -$3.85M | -$1.23M | -151.1% |
| Operating cash flow | -$42.09M | -$38.26M | -$31.71M | -$28.18M | -10.0% |
| Capital expenditure | -$12.00K | -$35.00K | -$137.00K | -$159.00K | +65.7% |
| Investing cash flow | -$94.11M | -$21.53M | $59.43M | -$107.37M | -337.1% |
| Financing cash flow | $121.01M | $61.48M | -$7.91M | $111.31M | +96.8% |
| Free cash flow | -$42.10M | -$38.29M | -$31.85M | -$28.33M | -10.0% |
| End cash position | $18.91M | $34.10M | $32.40M | $12.59M | -44.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $15.15M | $9.94M | $6.19M | $10.09M | $9.39M | +52.4% |
| Selling, general & admin | $5.36M | $4.97M | $4.03M | $3.83M | $4.33M | +7.8% |
| Total operating expense | $20.51M | $14.91M | $10.22M | $13.92M | $13.72M | +37.5% |
| Operating income | -$20.51M | -$14.91M | -$10.22M | -$13.92M | -$13.72M | -37.5% |
| Net interest income | $2.70M | $1.70M | $1.90M | $2.10M | $1.41M | +59.0% |
| Pre-tax income | -$17.82M | -$13.21M | -$8.33M | -$11.82M | -$12.32M | -34.8% |
| Tax provision | -$19.00K | -$20.00K | -$16.00K | -$15.00K | -$21.00K | +5.0% |
| Net income | -$17.80M | -$13.19M | -$8.32M | -$11.80M | -$12.30M | -34.9% |
| Net income to common | -$17.80M | -$13.19M | -$8.32M | -$11.80M | -$12.30M | -34.9% |
| Basic EPS | -0.11 | -0.09 | -0.06 | -0.08 | -0.09 | -22.2% |
| Diluted EPS | -0.11 | -0.09 | -0.06 | -0.08 | -0.09 | -22.2% |
| EBIT | -$20.51M | -$14.91M | -$8.33M | -$11.82M | -$13.72M | -37.5% |
| EBITDA | -$20.48M | -$14.88M | -$8.30M | -$11.78M | -$13.68M | -37.6% |
| Basic shares | 156.60M | 145.59M | 145.50M | 145.10M | 130.35M | +7.6% |
| Diluted shares | 156.60M | 145.59M | 145.50M | 145.10M | 130.35M | +7.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $54.30M | $19.41M | $18.91M | $56.87M | $117.06M | +179.7% |
| Cash & short-term investments | $318.87M | $171.78M | $188.26M | $194.93M | $203.88M | +85.6% |
| Total current assets | $325.70M | $176.12M | $191.66M | $198.30M | $207.23M | +84.9% |
| Property, plant & equipment | $878.00K | $875.00K | $855.00K | $954.00K | $1.04M | +0.3% |
| Total assets | $330.52M | $179.61M | $193.44M | $199.36M | $208.34M | +84.0% |
| Total current liabilities | $8.74M | $7.12M | $9.75M | $9.04M | $9.24M | +22.8% |
| Total debt | $605.00K | $682.00K | $753.00K | $823.00K | $891.00K | -11.3% |
| Total liabilities | $9.01M | $7.48M | $10.20M | $9.57M | $9.85M | +20.5% |
| Retained earnings | -$360.79M | -$343.00M | -$329.80M | -$321.49M | -$309.69M | -5.2% |
| Shareholder equity | $321.51M | $172.13M | $183.24M | $189.79M | $198.49M | +86.8% |
| Working capital | $316.97M | $169.01M | $181.91M | $189.26M | $197.99M | +87.5% |
| Net tangible assets | $321.51M | $172.13M | $183.24M | $189.79M | $198.49M | +86.8% |
| Shares issued | 141.98M | 128.41M | 128.31M | 128.22M | 121.78M | +10.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$17.80M | -$13.19M | -$8.32M | -$11.80M | -$12.30M | — | -34.9% |
| Depreciation & amortisation | $34.00K | $34.00K | $31.00K | $38.00K | $38.00K | — | 0.0% |
| Stock-based compensation | $3.27M | $2.19M | $1.35M | $1.24M | $1.38M | — | +49.3% |
| Change in working capital | -$2.52M | -$5.40M | -$274.00K | -$169.00K | $1.05M | — | +53.2% |
| Operating cash flow | -$17.43M | -$16.69M | -$7.63M | -$10.88M | -$10.10M | — | -4.4% |
| Capital expenditure | -$124.00K | -$102.00K | — | — | — | -$7.00K | -21.6% |
| Investing cash flow | -$112.04M | $16.96M | -$30.61M | -$50.94M | -$2.61M | — | -760.4% |
| Financing cash flow | $164.36M | $222.00K | $284.00K | $1.63M | $110.39M | — | +73,934.7% |
| Free cash flow | -$17.55M | -$16.79M | -$7.63M | -$10.89M | -$10.10M | — | -4.5% |
| End cash position | $54.30M | $19.41M | $18.91M | $56.87M | $117.06M | — | +179.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.23
-0.43% from price
SMA 20
18.29
-1.83% from price
SMA 50
17.74
+1.23% from price
SMA 100
15.83
+14.63% from price
SMA 200
13.73
+30.81% from price
EMA 12
18.29
-0.79% from price
EMA 26
18.09
+0.35% from price
EMA 50
17.44
+4.09% from price
RSI (14)
49.0
Neutral
MACD (12,26,9)
0.21
Hist -0.06
ATR (14)
0.83
4.61% of price
Realised vol 30D
69.6%
Annualised
Bollinger upper
18.96
20, 2σ
Bollinger lower
17.62
20, 2σ
50 / 200 cross
Golden
17.74 vs 13.73
Trend bias
Above 200
+30.81%
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
69.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-29.5%
Peak to trough
Max drawdown 5Y
-75.1%
Peak to trough
ATR 14
0.83
4.61% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Trevi Therapeutics Q2 Earnings Call Highlights
MarketBeat · 15d ago
Oppenheimer Adjusts Trevi Therapeutics PT to $25 From $24, Maintains Outperform Rating
MT Newswires · 15d ago
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ...
GuruFocus.com · 16d ago
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · 16d ago
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
GlobeNewswire · 23d ago
Trevi Therapeutics to Participate in Upcoming August Conferences
GlobeNewswire · 26d ago
BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target
MT Newswires · 33d ago
B. Riley Adjusts Trevi Therapeutics Price Target to $31 From $21, Maintains Buy Rating
MT Newswires · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.